Categories
Life Sciences Consumer Goods Materials and Chemicals Construction & Manufacturing Food and Beverages Energy and Power Semiconductor and Electronics Automotive and Transportation ICT & Media Aerospace & Defense BFSI

Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com

Dyslipidemia Drugs Market by Drug Type (Non-statins drugs, Statin drugs) and by DISTRIBUTION CHANNEL (Hospital pharmacy, Retail pharmacy, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032

A11423

Pages: NA

Charts: NA

Tables: NA

Dyslipidemia Drugs Market Outlook - 2027

Dyslipidemia is the unhealthy or abnormal levels of one or more kinds of lipids (fats) in patients’ blood stream. Blood contains three main types of lipid namely high-density lipoprotein (HDL), Low-Density lipoprotein (LDL), and triglycerides. Dyslipidemia, it usually means patient’s HDL levels are too low or patient’s LDL levels and triglycerides are high. The HDL is the good cholesterol because it helps to remove LDL from your blood. High LDL and triglycerides levels increase the risk of a heart attack and stroke. Low levels of HDL cholesterol are linked to higher heart disease risks. 

Dyslipidemia is divided into primary and secondary types. Primary dyslipidemia is inherited. Secondary dyslipidemia is an acquired condition. That means it develops from other causes, such as obesity or diabetes. The most commonly used medication to treat dyslipidemia is a statin. These medicines help reduce LDL levels by interfering with cholesterol production in the liver. Other non-statin drugs include ezetimibe (Zetia), fibrates, like fenofibrate, PCSK9 inhibitors.


COVID-19 scenario analysis:

Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicines supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine, have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are short of these drugs. Owing to the demand for vaccine and treatment drugs for COVID-19, the pharmaceutical and biotechnology industry is expected to witness a significant growth in the future.
Owing to such factors, COVID 19 is expected to have a significant impact on the Dyslipidemia drugs market.

Top impacting factors: Market Scenario Analysis, Trends, Drivers and Impact Analysis

The increase in the number of patients of dyslipidemia and diabetes pose the growth in the dyslipidemia drugs market. Increase in awareness of this disease through organizing various campaigns can drive the growth of the market. The governmental strategies to help the market may also fuel the dyslipidemia drugs market. The various new innovations in the drugs to treat the disease may also propel the growth of this market.

However, the requirement of great capital in the innovations for development in the field is posing as a restrain to the growth of the market.

New product launches to flourish the market:

  • Sanofi, a French pharmaceutical company launched Praluent, a novel dyslipidemia therapy in Korea in collaboration with Aventis Korea. This new therapy will work toward inhibiting the binding of PCSK9 to low-density lipoprotein receptors (LDLRs). This innovation will be able to fuel the growth of the market.
  • In January 2019, Amgen received approval for its proprietary drug Repatha from the National Medical Products Administration (NMPA) in China. The drug will be the first PCSK9 inhibitor medication for adults in China where the prevalence of dyslipidemia has increased in the recent past, triggering the demand for dyslipidemia therapeutics in the region.

Surge in usage in hospital applications:

Increase in the prevalence of dyslipidemia in the population, especially in the obese population, and growing awareness about dyslipidemia drugs that has been observed in the recent year will increase the demand for dyslipidemia drugs market. This increase in the awareness of new drug applications can surge the usage of dyslipidemia drugs in the hospital sector.

 

Key benefits of the report:

  • This study presents the analytical depiction of the global dyslipidemia drugs industry along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the global dyslipidemia drugs market share.
  • The current market is quantitatively analyzed to highlight the global dyslipidemia drugs market growth scenario.
  • Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
  • The report provides a detailed global dyslipidemia drugs market analysis based on competitive intensity and how the competition will take shape in coming years.

Questions answered in the dyslipidemia drugs market research report:

  • What are the leading market players active in the dyslipidemia drugs market?
  • What the current trends will influence the market in the next few years?
  • What are the driving factors, restraints, and opportunities in the market?
  • What are the projections for the future that would help in taking further strategic steps?

 Key Market Segments

  • By Drug Type
    • Non-statins drugs
      • Bile Acid Sequestrants
      • Cholesterol Absorption Inhibitor
      • Fibrates
      • Nicotinic Acid
      • Others
    • Statin drugs
      • High intensity
      • Moderate intensity
      • Low intensity
  • By DISTRIBUTION CHANNEL
    • Hospital pharmacy
    • Retail pharmacy
    • Others
  • By Region
    • North America
    • Europe
    • Asia-Pacific
    • Latin America
    • The Middle East and Africa

 
Key Market Players

  • Mylan N.V.
  • Abbott Laboratories.
  • Amgen, Inc.
  • Pfizer, Inc.
  • Merck & Co., Inc.
  • AstraZeneca plc
  • Shionogi & Co., Ltd.
  • Bayer AG
  • Novartis AG
  • Bristol-Myers Squibb Company

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

  • CHAPTER 4: DYSLIPIDEMIA DRUGS MARKET, BY DRUG TYPE

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Drug Type

    • 4.2. Non-statins Drugs

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

      • 4.2.4. Bile Acid Sequestrants

        • 4.2.4.1. Market Size and Forecast

      • 4.2.4. Cholesterol Absorption Inhibitor

        • 4.2.4.1. Market Size and Forecast

      • 4.2.4. Fibrates

        • 4.2.4.1. Market Size and Forecast

      • 4.2.4. Nicotinic Acid

        • 4.2.4.1. Market Size and Forecast

      • 4.2.4. Others

        • 4.2.4.1. Market Size and Forecast

    • 4.3. Statin Drugs

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

      • 4.3.4. High intensity

        • 4.3.4.1. Market Size and Forecast

      • 4.3.4. Moderate intensity

        • 4.3.4.1. Market Size and Forecast

      • 4.3.4. Low intensity

        • 4.3.4.1. Market Size and Forecast

  • CHAPTER 5: DYSLIPIDEMIA DRUGS MARKET, BY DISTRIBUTION CHANNEL

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Distribution Channel

    • 5.2. Hospital Pharmacy

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Retail Pharmacy

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Others

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

  • CHAPTER 6: DYSLIPIDEMIA DRUGS MARKET, BY REGION

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Region

    • 6.2. North America

      • 6.2.1. Key Market Trends and Opportunities

      • 6.2.2. Market Size and Forecast, By Drug Type

      • 6.2.3. Market Size and Forecast, By Distribution Channel

      • 6.2.4. Market Size and Forecast, By Country

      • 6.2.5. U.S. Dyslipidemia Drugs Market

        • 6.2.5.1. Market Size and Forecast, By Drug Type
        • 6.2.5.2. Market Size and Forecast, By Distribution Channel

      • 6.2.6. Canada Dyslipidemia Drugs Market

        • 6.2.6.1. Market Size and Forecast, By Drug Type
        • 6.2.6.2. Market Size and Forecast, By Distribution Channel

      • 6.2.7. Mexico Dyslipidemia Drugs Market

        • 6.2.7.1. Market Size and Forecast, By Drug Type
        • 6.2.7.2. Market Size and Forecast, By Distribution Channel

    • 6.3. Europe

      • 6.3.1. Key Market Trends and Opportunities

      • 6.3.2. Market Size and Forecast, By Drug Type

      • 6.3.3. Market Size and Forecast, By Distribution Channel

      • 6.3.4. Market Size and Forecast, By Country

      • 6.3.5. France Dyslipidemia Drugs Market

        • 6.3.5.1. Market Size and Forecast, By Drug Type
        • 6.3.5.2. Market Size and Forecast, By Distribution Channel

      • 6.3.6. Germany Dyslipidemia Drugs Market

        • 6.3.6.1. Market Size and Forecast, By Drug Type
        • 6.3.6.2. Market Size and Forecast, By Distribution Channel

      • 6.3.7. Italy Dyslipidemia Drugs Market

        • 6.3.7.1. Market Size and Forecast, By Drug Type
        • 6.3.7.2. Market Size and Forecast, By Distribution Channel

      • 6.3.8. Spain Dyslipidemia Drugs Market

        • 6.3.8.1. Market Size and Forecast, By Drug Type
        • 6.3.8.2. Market Size and Forecast, By Distribution Channel

      • 6.3.9. UK Dyslipidemia Drugs Market

        • 6.3.9.1. Market Size and Forecast, By Drug Type
        • 6.3.9.2. Market Size and Forecast, By Distribution Channel

      • 6.3.10. Russia Dyslipidemia Drugs Market

        • 6.3.10.1. Market Size and Forecast, By Drug Type
        • 6.3.10.2. Market Size and Forecast, By Distribution Channel

      • 6.3.11. Rest Of Europe Dyslipidemia Drugs Market

        • 6.3.11.1. Market Size and Forecast, By Drug Type
        • 6.3.11.2. Market Size and Forecast, By Distribution Channel

    • 6.4. Asia-Pacific

      • 6.4.1. Key Market Trends and Opportunities

      • 6.4.2. Market Size and Forecast, By Drug Type

      • 6.4.3. Market Size and Forecast, By Distribution Channel

      • 6.4.4. Market Size and Forecast, By Country

      • 6.4.5. China Dyslipidemia Drugs Market

        • 6.4.5.1. Market Size and Forecast, By Drug Type
        • 6.4.5.2. Market Size and Forecast, By Distribution Channel

      • 6.4.6. Japan Dyslipidemia Drugs Market

        • 6.4.6.1. Market Size and Forecast, By Drug Type
        • 6.4.6.2. Market Size and Forecast, By Distribution Channel

      • 6.4.7. India Dyslipidemia Drugs Market

        • 6.4.7.1. Market Size and Forecast, By Drug Type
        • 6.4.7.2. Market Size and Forecast, By Distribution Channel

      • 6.4.8. South Korea Dyslipidemia Drugs Market

        • 6.4.8.1. Market Size and Forecast, By Drug Type
        • 6.4.8.2. Market Size and Forecast, By Distribution Channel

      • 6.4.9. Australia Dyslipidemia Drugs Market

        • 6.4.9.1. Market Size and Forecast, By Drug Type
        • 6.4.9.2. Market Size and Forecast, By Distribution Channel

      • 6.4.10. Thailand Dyslipidemia Drugs Market

        • 6.4.10.1. Market Size and Forecast, By Drug Type
        • 6.4.10.2. Market Size and Forecast, By Distribution Channel

      • 6.4.11. Malaysia Dyslipidemia Drugs Market

        • 6.4.11.1. Market Size and Forecast, By Drug Type
        • 6.4.11.2. Market Size and Forecast, By Distribution Channel

      • 6.4.12. Indonesia Dyslipidemia Drugs Market

        • 6.4.12.1. Market Size and Forecast, By Drug Type
        • 6.4.12.2. Market Size and Forecast, By Distribution Channel

      • 6.4.13. Rest of Asia Pacific Dyslipidemia Drugs Market

        • 6.4.13.1. Market Size and Forecast, By Drug Type
        • 6.4.13.2. Market Size and Forecast, By Distribution Channel

    • 6.5. LAMEA

      • 6.5.1. Key Market Trends and Opportunities

      • 6.5.2. Market Size and Forecast, By Drug Type

      • 6.5.3. Market Size and Forecast, By Distribution Channel

      • 6.5.4. Market Size and Forecast, By Country

      • 6.5.5. Brazil Dyslipidemia Drugs Market

        • 6.5.5.1. Market Size and Forecast, By Drug Type
        • 6.5.5.2. Market Size and Forecast, By Distribution Channel

      • 6.5.6. South Africa Dyslipidemia Drugs Market

        • 6.5.6.1. Market Size and Forecast, By Drug Type
        • 6.5.6.2. Market Size and Forecast, By Distribution Channel

      • 6.5.7. Saudi Arabia Dyslipidemia Drugs Market

        • 6.5.7.1. Market Size and Forecast, By Drug Type
        • 6.5.7.2. Market Size and Forecast, By Distribution Channel

      • 6.5.8. UAE Dyslipidemia Drugs Market

        • 6.5.8.1. Market Size and Forecast, By Drug Type
        • 6.5.8.2. Market Size and Forecast, By Distribution Channel

      • 6.5.9. Argentina Dyslipidemia Drugs Market

        • 6.5.9.1. Market Size and Forecast, By Drug Type
        • 6.5.9.2. Market Size and Forecast, By Distribution Channel

      • 6.5.10. Rest of LAMEA Dyslipidemia Drugs Market

        • 6.5.10.1. Market Size and Forecast, By Drug Type
        • 6.5.10.2. Market Size and Forecast, By Distribution Channel

  • CHAPTER 7: COMPETITIVE LANDSCAPE

    • 7.1. Introduction

    • 7.2. Top Winning Strategies

    • 7.3. Product Mapping Of Top 10 Player

    • 7.4. Competitive Dashboard

    • 7.5. Competitive Heatmap

    • 7.6. Top Player Positioning, 2024

  • CHAPTER 8: COMPANY PROFILES

    • 8.1. Shionogi And Co., Ltd.

      • 8.1.1. Company Overview

      • 8.1.2. Key Executives

      • 8.1.3. Company Snapshot

      • 8.1.4. Operating Business Segments

      • 8.1.5. Product Portfolio

      • 8.1.6. Business Performance

      • 8.1.7. Key Strategic Moves and Developments

    • 8.2. Pfizer, Inc.

      • 8.2.1. Company Overview

      • 8.2.2. Key Executives

      • 8.2.3. Company Snapshot

      • 8.2.4. Operating Business Segments

      • 8.2.5. Product Portfolio

      • 8.2.6. Business Performance

      • 8.2.7. Key Strategic Moves and Developments

    • 8.3. Merck And Co., Inc.

      • 8.3.1. Company Overview

      • 8.3.2. Key Executives

      • 8.3.3. Company Snapshot

      • 8.3.4. Operating Business Segments

      • 8.3.5. Product Portfolio

      • 8.3.6. Business Performance

      • 8.3.7. Key Strategic Moves and Developments

    • 8.4. Novartis AG

      • 8.4.1. Company Overview

      • 8.4.2. Key Executives

      • 8.4.3. Company Snapshot

      • 8.4.4. Operating Business Segments

      • 8.4.5. Product Portfolio

      • 8.4.6. Business Performance

      • 8.4.7. Key Strategic Moves and Developments

    • 8.5. Bayer AG

      • 8.5.1. Company Overview

      • 8.5.2. Key Executives

      • 8.5.3. Company Snapshot

      • 8.5.4. Operating Business Segments

      • 8.5.5. Product Portfolio

      • 8.5.6. Business Performance

      • 8.5.7. Key Strategic Moves and Developments

    • 8.6. Bristol-Myers Squibb Company

      • 8.6.1. Company Overview

      • 8.6.2. Key Executives

      • 8.6.3. Company Snapshot

      • 8.6.4. Operating Business Segments

      • 8.6.5. Product Portfolio

      • 8.6.6. Business Performance

      • 8.6.7. Key Strategic Moves and Developments

    • 8.7. Mylan N.V.

      • 8.7.1. Company Overview

      • 8.7.2. Key Executives

      • 8.7.3. Company Snapshot

      • 8.7.4. Operating Business Segments

      • 8.7.5. Product Portfolio

      • 8.7.6. Business Performance

      • 8.7.7. Key Strategic Moves and Developments

    • 8.8. Amgen, Inc.

      • 8.8.1. Company Overview

      • 8.8.2. Key Executives

      • 8.8.3. Company Snapshot

      • 8.8.4. Operating Business Segments

      • 8.8.5. Product Portfolio

      • 8.8.6. Business Performance

      • 8.8.7. Key Strategic Moves and Developments

    • 8.9. AstraZeneca Plc

      • 8.9.1. Company Overview

      • 8.9.2. Key Executives

      • 8.9.3. Company Snapshot

      • 8.9.4. Operating Business Segments

      • 8.9.5. Product Portfolio

      • 8.9.6. Business Performance

      • 8.9.7. Key Strategic Moves and Developments

    • 8.10. Abbott Laboratories.

      • 8.10.1. Company Overview

      • 8.10.2. Key Executives

      • 8.10.3. Company Snapshot

      • 8.10.4. Operating Business Segments

      • 8.10.5. Product Portfolio

      • 8.10.6. Business Performance

      • 8.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL DYSLIPIDEMIA DRUGS MARKET, BY DRUG TYPE, 2025-2033 ($MILLION)
  • TABLE 2. GLOBAL DYSLIPIDEMIA DRUGS MARKET FOR NON-STATINS DRUGS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 3. GLOBAL DYSLIPIDEMIA DRUGS MARKET FOR STATIN DRUGS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 4. GLOBAL DYSLIPIDEMIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 5. GLOBAL DYSLIPIDEMIA DRUGS MARKET FOR HOSPITAL PHARMACY, BY REGION, 2025-2033 ($MILLION)
  • TABLE 6. GLOBAL DYSLIPIDEMIA DRUGS MARKET FOR RETAIL PHARMACY, BY REGION, 2025-2033 ($MILLION)
  • TABLE 7. GLOBAL DYSLIPIDEMIA DRUGS MARKET FOR OTHERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 8. GLOBAL DYSLIPIDEMIA DRUGS MARKET, BY REGION, 2025-2033 ($MILLION)
  • TABLE 9. NORTH AMERICA DYSLIPIDEMIA DRUGS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 10. NORTH AMERICA DYSLIPIDEMIA DRUGS, BY DRUG TYPE, 2025-2033 ($MILLION)
  • TABLE 11. NORTH AMERICA DYSLIPIDEMIA DRUGS, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 12. U.S. DYSLIPIDEMIA DRUGS, BY DRUG TYPE, 2025-2033 ($MILLION)
  • TABLE 13. U.S. DYSLIPIDEMIA DRUGS, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 14. CANADA DYSLIPIDEMIA DRUGS, BY DRUG TYPE, 2025-2033 ($MILLION)
  • TABLE 15. CANADA DYSLIPIDEMIA DRUGS, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 16. MEXICO DYSLIPIDEMIA DRUGS, BY DRUG TYPE, 2025-2033 ($MILLION)
  • TABLE 17. MEXICO DYSLIPIDEMIA DRUGS, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 18. EUROPE DYSLIPIDEMIA DRUGS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 19. EUROPE DYSLIPIDEMIA DRUGS, BY DRUG TYPE, 2025-2033 ($MILLION)
  • TABLE 20. EUROPE DYSLIPIDEMIA DRUGS, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 21. FRANCE DYSLIPIDEMIA DRUGS, BY DRUG TYPE, 2025-2033 ($MILLION)
  • TABLE 22. FRANCE DYSLIPIDEMIA DRUGS, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 23. GERMANY DYSLIPIDEMIA DRUGS, BY DRUG TYPE, 2025-2033 ($MILLION)
  • TABLE 24. GERMANY DYSLIPIDEMIA DRUGS, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 25. ITALY DYSLIPIDEMIA DRUGS, BY DRUG TYPE, 2025-2033 ($MILLION)
  • TABLE 26. ITALY DYSLIPIDEMIA DRUGS, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 27. SPAIN DYSLIPIDEMIA DRUGS, BY DRUG TYPE, 2025-2033 ($MILLION)
  • TABLE 28. SPAIN DYSLIPIDEMIA DRUGS, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 29. UK DYSLIPIDEMIA DRUGS, BY DRUG TYPE, 2025-2033 ($MILLION)
  • TABLE 30. UK DYSLIPIDEMIA DRUGS, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 31. RUSSIA DYSLIPIDEMIA DRUGS, BY DRUG TYPE, 2025-2033 ($MILLION)
  • TABLE 32. RUSSIA DYSLIPIDEMIA DRUGS, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 33. REST OF EUROPE DYSLIPIDEMIA DRUGS, BY DRUG TYPE, 2025-2033 ($MILLION)
  • TABLE 34. REST OF EUROPE DYSLIPIDEMIA DRUGS, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 35. ASIA-PACIFIC DYSLIPIDEMIA DRUGS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 36. ASIA-PACIFIC DYSLIPIDEMIA DRUGS, BY DRUG TYPE, 2025-2033 ($MILLION)
  • TABLE 37. ASIA-PACIFIC DYSLIPIDEMIA DRUGS, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 38. CHINA DYSLIPIDEMIA DRUGS, BY DRUG TYPE, 2025-2033 ($MILLION)
  • TABLE 39. CHINA DYSLIPIDEMIA DRUGS, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 40. JAPAN DYSLIPIDEMIA DRUGS, BY DRUG TYPE, 2025-2033 ($MILLION)
  • TABLE 41. JAPAN DYSLIPIDEMIA DRUGS, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 42. INDIA DYSLIPIDEMIA DRUGS, BY DRUG TYPE, 2025-2033 ($MILLION)
  • TABLE 43. INDIA DYSLIPIDEMIA DRUGS, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 44. SOUTH KOREA DYSLIPIDEMIA DRUGS, BY DRUG TYPE, 2025-2033 ($MILLION)
  • TABLE 45. SOUTH KOREA DYSLIPIDEMIA DRUGS, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 46. AUSTRALIA DYSLIPIDEMIA DRUGS, BY DRUG TYPE, 2025-2033 ($MILLION)
  • TABLE 47. AUSTRALIA DYSLIPIDEMIA DRUGS, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 48. THAILAND DYSLIPIDEMIA DRUGS, BY DRUG TYPE, 2025-2033 ($MILLION)
  • TABLE 49. THAILAND DYSLIPIDEMIA DRUGS, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 50. MALAYSIA DYSLIPIDEMIA DRUGS, BY DRUG TYPE, 2025-2033 ($MILLION)
  • TABLE 51. MALAYSIA DYSLIPIDEMIA DRUGS, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 52. INDONESIA DYSLIPIDEMIA DRUGS, BY DRUG TYPE, 2025-2033 ($MILLION)
  • TABLE 53. INDONESIA DYSLIPIDEMIA DRUGS, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 54. REST OF ASIA PACIFIC DYSLIPIDEMIA DRUGS, BY DRUG TYPE, 2025-2033 ($MILLION)
  • TABLE 55. REST OF ASIA PACIFIC DYSLIPIDEMIA DRUGS, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 56. LAMEA DYSLIPIDEMIA DRUGS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 57. LAMEA DYSLIPIDEMIA DRUGS, BY DRUG TYPE, 2025-2033 ($MILLION)
  • TABLE 58. LAMEA DYSLIPIDEMIA DRUGS, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 59. BRAZIL DYSLIPIDEMIA DRUGS, BY DRUG TYPE, 2025-2033 ($MILLION)
  • TABLE 60. BRAZIL DYSLIPIDEMIA DRUGS, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 61. SOUTH AFRICA DYSLIPIDEMIA DRUGS, BY DRUG TYPE, 2025-2033 ($MILLION)
  • TABLE 62. SOUTH AFRICA DYSLIPIDEMIA DRUGS, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 63. SAUDI ARABIA DYSLIPIDEMIA DRUGS, BY DRUG TYPE, 2025-2033 ($MILLION)
  • TABLE 64. SAUDI ARABIA DYSLIPIDEMIA DRUGS, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 65. UAE DYSLIPIDEMIA DRUGS, BY DRUG TYPE, 2025-2033 ($MILLION)
  • TABLE 66. UAE DYSLIPIDEMIA DRUGS, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 67. ARGENTINA DYSLIPIDEMIA DRUGS, BY DRUG TYPE, 2025-2033 ($MILLION)
  • TABLE 68. ARGENTINA DYSLIPIDEMIA DRUGS, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 69. REST OF LAMEA DYSLIPIDEMIA DRUGS, BY DRUG TYPE, 2025-2033 ($MILLION)
  • TABLE 70. REST OF LAMEA DYSLIPIDEMIA DRUGS, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 71. SHIONOGI AND CO., LTD.: KEY EXECUTIVES
  • TABLE 72. SHIONOGI AND CO., LTD.: COMPANY SNAPSHOT
  • TABLE 73. SHIONOGI AND CO., LTD.: OPERATING SEGMENTS
  • TABLE 74. SHIONOGI AND CO., LTD.: PRODUCT PORTFOLIO
  • TABLE 75. SHIONOGI AND CO., LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 76. PFIZER, INC.: KEY EXECUTIVES
  • TABLE 77. PFIZER, INC.: COMPANY SNAPSHOT
  • TABLE 78. PFIZER, INC.: OPERATING SEGMENTS
  • TABLE 79. PFIZER, INC.: PRODUCT PORTFOLIO
  • TABLE 80. PFIZER, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 81. MERCK AND CO., INC.: KEY EXECUTIVES
  • TABLE 82. MERCK AND CO., INC.: COMPANY SNAPSHOT
  • TABLE 83. MERCK AND CO., INC.: OPERATING SEGMENTS
  • TABLE 84. MERCK AND CO., INC.: PRODUCT PORTFOLIO
  • TABLE 85. MERCK AND CO., INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 86. NOVARTIS AG: KEY EXECUTIVES
  • TABLE 87. NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 88. NOVARTIS AG: OPERATING SEGMENTS
  • TABLE 89. NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 90. NOVARTIS AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 91. BAYER AG: KEY EXECUTIVES
  • TABLE 92. BAYER AG: COMPANY SNAPSHOT
  • TABLE 93. BAYER AG: OPERATING SEGMENTS
  • TABLE 94. BAYER AG: PRODUCT PORTFOLIO
  • TABLE 95. BAYER AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 96. BRISTOL-MYERS SQUIBB COMPANY: KEY EXECUTIVES
  • TABLE 97. BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT
  • TABLE 98. BRISTOL-MYERS SQUIBB COMPANY: OPERATING SEGMENTS
  • TABLE 99. BRISTOL-MYERS SQUIBB COMPANY: PRODUCT PORTFOLIO
  • TABLE 100. BRISTOL-MYERS SQUIBB COMPANY: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 101. MYLAN N.V.: KEY EXECUTIVES
  • TABLE 102. MYLAN N.V.: COMPANY SNAPSHOT
  • TABLE 103. MYLAN N.V.: OPERATING SEGMENTS
  • TABLE 104. MYLAN N.V.: PRODUCT PORTFOLIO
  • TABLE 105. MYLAN N.V.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 106. AMGEN, INC.: KEY EXECUTIVES
  • TABLE 107. AMGEN, INC.: COMPANY SNAPSHOT
  • TABLE 108. AMGEN, INC.: OPERATING SEGMENTS
  • TABLE 109. AMGEN, INC.: PRODUCT PORTFOLIO
  • TABLE 110. AMGEN, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 111. ASTRAZENECA PLC: KEY EXECUTIVES
  • TABLE 112. ASTRAZENECA PLC: COMPANY SNAPSHOT
  • TABLE 113. ASTRAZENECA PLC: OPERATING SEGMENTS
  • TABLE 114. ASTRAZENECA PLC: PRODUCT PORTFOLIO
  • TABLE 115. ASTRAZENECA PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 116. ABBOTT LABORATORIES.: KEY EXECUTIVES
  • TABLE 117. ABBOTT LABORATORIES.: COMPANY SNAPSHOT
  • TABLE 118. ABBOTT LABORATORIES.: OPERATING SEGMENTS
  • TABLE 119. ABBOTT LABORATORIES.: PRODUCT PORTFOLIO
  • TABLE 120. ABBOTT LABORATORIES.: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL DYSLIPIDEMIA DRUGS MARKET SEGMENTATION
  • FIGURE 2. GLOBAL DYSLIPIDEMIA DRUGS MARKET
  • FIGURE 3. SEGMENTATION DYSLIPIDEMIA DRUGS MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN DYSLIPIDEMIA DRUGS MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALDYSLIPIDEMIA DRUGS MARKET
  • FIGURE 11. DYSLIPIDEMIA DRUGS MARKET SEGMENTATION, BY BY DRUG TYPE
  • FIGURE 12. DYSLIPIDEMIA DRUGS MARKET FOR NON-STATINS DRUGS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 13. DYSLIPIDEMIA DRUGS MARKET FOR STATIN DRUGS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 14. DYSLIPIDEMIA DRUGS MARKET SEGMENTATION, BY BY DISTRIBUTION CHANNEL
  • FIGURE 15. DYSLIPIDEMIA DRUGS MARKET FOR HOSPITAL PHARMACY, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 16. DYSLIPIDEMIA DRUGS MARKET FOR RETAIL PHARMACY, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 17. DYSLIPIDEMIA DRUGS MARKET FOR OTHERS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 18. TOP WINNING STRATEGIES, BY YEAR, 2022-2024*
  • FIGURE 19. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2022-2024*
  • FIGURE 20. TOP WINNING STRATEGIES, BY COMPANY, 2022-2024*
  • FIGURE 21. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 22. COMPETITIVE DASHBOARD
  • FIGURE 23. COMPETITIVE HEATMAP: DYSLIPIDEMIA DRUGS MARKET
  • FIGURE 24. TOP PLAYER POSITIONING, 2024
  • FIGURE 25. SHIONOGI AND CO., LTD.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 26. SHIONOGI AND CO., LTD.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 27. SHIONOGI AND CO., LTD.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 28. PFIZER, INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 29. PFIZER, INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 30. PFIZER, INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 31. MERCK AND CO., INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 32. MERCK AND CO., INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 33. MERCK AND CO., INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 34. NOVARTIS AG: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 35. NOVARTIS AG: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 36. NOVARTIS AG: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 37. BAYER AG: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 38. BAYER AG: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 39. BAYER AG: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 40. BRISTOL-MYERS SQUIBB COMPANY: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 41. BRISTOL-MYERS SQUIBB COMPANY: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 42. BRISTOL-MYERS SQUIBB COMPANY: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 43. MYLAN N.V.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 44. MYLAN N.V.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 45. MYLAN N.V.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 46. AMGEN, INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 47. AMGEN, INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 48. AMGEN, INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 49. ASTRAZENECA PLC: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 50. ASTRAZENECA PLC: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 51. ASTRAZENECA PLC: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 52. ABBOTT LABORATORIES.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 53. ABBOTT LABORATORIES.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 54. ABBOTT LABORATORIES.: REVENUE SHARE, BY REGION, 2024 (%)

Purchase Full Report of
Dyslipidemia Drugs Market

PURCHASE OPTIONS



* Taxes/Fees, If applicable will be added during checkout. All prices in USD.

Have a question ?

Need to add more ?

Avail up to 30% discount on subscription plans on


Avenue

© 2025 Allied Market Research. All Rights Reserved